InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,672.40
(
0.16%
)
Dow Jones
39,308.00
(
0.00%
)
Brent Oil
87.16
(
-0.20%
)
Bitcoin
55,492.02
(
-2.61%
)
Post# of 252487
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Titan V post# 223773

Wednesday, 05/08/2019 8:21:25 AM

Wednesday, May 08, 2019 8:21:25 AM

Post# of 252487
Re: RSV vaccine from MRK/MRNA

From MRNA’s 1Q19 PR:

https://finance.yahoo.com/news/moderna-reports-first-quarter-2019-110000485.html

Respiratory syncytial virus (RSV) vaccine (mRNA-1777 and mRNA-1172): Merck…plans to run a Phase 1 study for a follow-on development candidate (mRNA-1172), a vaccine for RSV which has shown enhanced potency in preclinical studies and uses a Merck proprietary formulation. As a result, further development of mRNA-1777 has been paused…

h/t @bio_clouseau.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up